Another tumour-promoting lncRNA, LINC01929, accelerates the tumour progression by targeting the miR-137-3p/FOXC1 axis in OSCC, suggesting a novel target for OSCC therapy [137]. The gene discussed is FOXC1; the disease is neoplasm.